Skip To Main Content
Denne hjemmeside er forbeholdt sundhedspersoner, der bor og/eller arbejder i Danmark
Campus
  • Webshop
  • Uddannelse
  • Artikel
  • Reumatologi
  • Materiale
  • Vacciner
Campus
  • Webshop
  • Uddannelse
  • Artikel
  • Reumatologi
  • Materiale
  • Vacciner
View Full Results

Type 2 diabetes

Artikel

Switching from other basal insulins to Toujeo<sup>®</sup> (Insulin Glargine)

Switching from other basal insulins to Toujeo (Insulin Glargine)

Læs mere
Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?<sup>1</sup>

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Læs mere
When to Initiate Basal Insulin?

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Læs mere
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Læs mere
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Læs mere
Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Læs mere

Uddannelse

Personalized approach in T2D is key for success

Personalized approach in T2D is key for success

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.

Læs mere